Balance Sheet IRLAB Therapeutics AB

Stocks

IRLAB A

SE0012675361

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 15/06/2026 BST			5-day change	1st Jan Change
1.200 ^SEK	-3.38%		-5.36%	-39.09%

06-08	Irlab shares trade ex-rights on Nasdaq Stockholm following rights issue	FW
06-05	IRLAB Therapeutics AB Announces Board Elections, Effective June 5, 2026	CI

cfc1ee4a1903be0b312d300.thisYOIlL_kE2r5n0rg2KvY-S2_lr5ECMEU6kfDfE04.7lT-VIVqapdR6-9Q4Y9Ee55Kf1uv6eE0VRZu-ceYXw2FUJUGk24YiEGryQ

Published financial data: IRLAB THERAPEUTICS AB

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	-	208M	61.14M	5.68M	94.63M
Other Revenues, Total	300K	-	-	-	-
Total Revenues	300K	208M	61.14M	5.68M	94.63M
Cost of Goods Sold, Total	65.63M	81.74M	126M	128M	136M
Gross Profit	-65.33M	126M	-64.77M	-123M	-41.66M
Selling General & Admin Expenses, Total	23.97M	31.02M	42.48M	53.08M	46.18M
Depreciation & Amortization - (IS)	2.26M	3.47M	4.78M	4.32M	4.58M
Other Operating Expenses	-96K	38.97M	-27K	-42K	-19.46M
Other Operating Expenses, Total	26.13M	73.47M	47.23M	57.36M	31.31M
Operating Income	-91.46M	52.58M	-112M	-180M	-72.97M
Interest Expense, Total	-195K	-370K	-297K	-199K	-10.48M
Interest And Investment Income	1K	1K	-	3.12M	2.46M
Net Interest Expenses	-194K	-369K	-297K	2.93M	-8.02M
Currency Exchange Gains (Loss)	-	-426K	-1.11M	-676K	-2.14M
Other Non Operating Income (Expenses)	-1K	-	-	1K	-
EBT, Excl. Unusual Items	-91.65M	51.78M	-113M	-178M	-83.13M
Asset Writedown	-	-	-	-	-
Insurance Settlements	-	-	-	-	-
EBT, Incl. Unusual Items	-91.65M	51.78M	-113M	-178M	-83.13M
Income Tax Expense	-	-	-	-	-
Earnings From Continuing Operations	-91.65M	51.78M	-113M	-178M	-83.13M
Net Income to Company	-91.65M	51.78M	-113M	-178M	-83.13M
Minority Interest	-	-	-	-	-
Net Income - (IS)	-91.65M	51.78M	-113M	-178M	-83.13M
Net Income to Common Incl Extra Items	-91.65M	51.78M	-113M	-178M	-83.13M
Net Income to Common Excl. Extra Items	-91.65M	51.78M	-113M	-178M	-83.13M
Per Share Items
Net EPS - Basic	-1.92	1	-2.19	-3.43	-1.6
Basic EPS - Continuing Operations	-1.92	1	-2.19	-3.43	-1.6
Basic Weighted Average Shares Outstanding	47.68M	51.75M	51.83M	51.87M	51.87M
Net EPS - Diluted	-1.92	1	-2.19	-3.43	-1.6
Diluted EPS - Continuing Operations	-1.92	1	-2.19	-3.43	-1.6
Diluted Weighted Average Shares Outstanding	47.68M	51.75M	51.83M	51.87M	51.87M
Normalized Basic EPS	-1.2	0.63	-1.37	-2.14	-1
Normalized Diluted EPS	-1.2	0.63	-1.37	-2.14	-1
Supplemental Items
EBITDA	-91.12M	53.07M	-111M	-179M	-72.08M
EBITA	-91.46M	52.58M	-112M	-180M	-72.97M
EBIT	-91.46M	52.58M	-112M	-180M	-72.97M
EBITDAR	-91M	53.26M	-	-	-
Total Revenues (As Reported)	404K	208M	61.28M	5.72M	114M
Effective Tax Rate - (Ratio)	-	-	-	-	-
Deferred Domestic Taxes	-	-	-	-	-
Total Deferred Taxes	-	-	-	-	-
Normalized Net Income	-57.28M	32.36M	-70.88M	-111M	-51.96M
Interest on Long-Term Debt	193K	367K	-	-	-
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	75.99M	130M	146M	151M	164M
Net Rental Expense, Total	130K	187K	-	-	-
Imputed Operating Lease Interest Expense	54.3K	116K	-	-	-
Imputed Operating Lease Depreciation	75.7K	70.8K	-	-	-

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	277M	402M	253M	111M	66.92M
Total Cash And Short Term Investments	277M	402M	253M	111M	66.92M
Accounts Receivable, Total	-	4.47M	3.32M	-	-
Other Receivables	4.71M	6.27M	8.9M	9.17M	10.08M
Total Receivables	4.71M	10.74M	12.22M	9.17M	10.08M
Prepaid Expenses	2.02M	2.28M	3.34M	2.8M	2.2M
Other Current Assets, Total	1K	6.52M	346K	314K	367K
Total Current Assets	284M	421M	269M	124M	79.56M
Gross Property Plant And Equipment	9.6M	16.71M	20.09M	23.07M	30.77M
Accumulated Depreciation	-5.28M	-8.36M	-12.08M	-16.4M	-20.98M
Net Property Plant And Equipment	4.32M	8.35M	8.01M	6.67M	9.79M
Other Intangibles, Total	81.49M	42.4M	46.86M	46.86M	46.86M
Deferred Charges Long-Term	518K	259K	-	-	-
Other Long-Term Assets, Total	-	-1K	-1K	-	-1K
Total Assets	370M	472M	324M	177M	136M
Liabilities
Accounts Payable, Total	3.68M	12.3M	10.03M	10.52M	9.94M
Accrued Expenses, Total	11.8M	5.84M	13.44M	14.91M	11.68M
Short-term Borrowings	-	-	-	-	53.47M
Current Portion of Leases	1.66M	3.03M	3.6M	2.94M	3.42M
Unearned Revenue Current, Total	-	42.58M	-	-	-
Other Current Liabilities	3.77M	5.65M	5.28M	8.35M	21.54M
Total Current Liabilities	20.92M	69.4M	32.34M	36.73M	100M
Long-Term Debt	-	-	-	24.51M	-
Long-Term Leases	1.27M	3.57M	381K	115K	3.54M
Deferred Tax Liability Non Current	-	-	-	-	-
Other Non Current Liabilities	-	-	-	-	-
Total Liabilities	22.19M	72.97M	32.72M	61.36M	104M
Common Stock, Total	970K	1.04M	1.04M	1.04M	1.04M
Additional Paid In Capital	686M	685M	690M	690M	690M
Retained Earnings	-339M	-287M	-400M	-575M	-659M
Comprehensive Income and Other	66K	-	-	-	1K
Total Common Equity	348M	399M	291M	116M	32.64M
Total Equity	348M	399M	291M	116M	32.64M
Total Liabilities And Equity	370M	472M	324M	177M	136M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	51.75M	51.75M	51.87M	51.87M	51.87M
ECS Total Common Shares Outstanding	51.75M	51.75M	-	51.87M	51.87M
Book Value / Share	6.72	7.72	5.61	2.23	0.63
Tangible Book Value	266M	357M	244M	68.9M	-14.23M
Tangible Book Value Per Share	5.15	6.9	4.7	1.33	-0.27
Total Debt	2.93M	6.6M	3.98M	27.57M	60.42M
Net Debt	-274M	-395M	-249M	-83.74M	-6.5M
Debt Equivalent Oper. Leases	1.04M	1.5M	-	-	-
Account Code - Inventory Valuation	3	3	-	3	3
Machinery, Total	2.94M	3.65M	6.53M	6.82M	7.02M
Full Time Employees	20	27	-	34	31

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	-91.65M	51.78M	-113M	-178M	-83.13M
Depreciation & Amortization - CF	2M	3.22M	3.72M	4.32M	4.58M
Depreciation & Amortization, Total	2M	3.22M	3.72M	4.32M	4.58M
Amortization of Deferred Charges, Total - (CF)	259K	259K	259K	-	-
Asset Writedown & Restructuring Costs	-	-	797K	-	-
Other Operating Activities, Total	0	39.09M	0	0	3.96M
Change In Accounts Receivable	2.62M	-12.81M	3.63M	3.63M	2.79M
Change in Other Net Operating Assets	-2.44M	47.11M	-37.62M	5.04M	6.21M
Cash from Operations	-89.21M	129M	-143M	-165M	-65.59M
Capital Expenditure	-394K	-708K	-2.88M	-293K	-199K
Sale (Purchase) of Intangible assets	-	-	-500K	-	-
Cash from Investing	-394K	-708K	-3.38M	-293K	-199K
Long-Term Debt Issued, Total	-	-	-	27.28M	25M
Total Debt Issued	-	-	-	27.28M	25M
Long-Term Debt Repaid, Total	-1.62M	-2.86M	-3.13M	-3.61M	-3.6M
Total Debt Repaid	-1.62M	-2.86M	-3.13M	-3.61M	-3.6M
Issuance of Common Stock	275M	-	-	-	-
Other Financing Activities, Total	-17.79M	-180K	-	-	-
Cash from Financing	256M	-3.04M	-3.13M	23.68M	21.4M
Miscellaneous Cash Flow Adjustments	-1K	-	1K	-	1K
Net Change in Cash	166M	125M	-149M	-141M	-44.39M
Supplemental Items
Cash Interest Paid	196K	796K	297K	199K	6.52M
Levered Free Cash Flow	-55.24M	69.69M	-104M	-99.98M	-38.77M
Unlevered Free Cash Flow	-55.12M	69.92M	-103M	-99.86M	-32.22M
Change In Net Working Capital	-183K	-34.3M	33.98M	-8.67M	-9M
Net Debt Issued / Repaid	-1.62M	-2.86M	-3.13M	23.68M	21.4M

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	-19.77	7.8	-17.59	-44.96	-29.11
Return on Total Capital	-21.28	8.68	-19.98	-51.38	-38.59
Return On Equity %	-34.61	13.86	-32.86	-87.48	-112.03
Return on Common Equity	-34.61	13.86	-32.86	-87.48	-112.03
Margin Analysis
Gross Profit Margin %	-21.78K	60.66	-105.94	-2.16K	-44.03
SG&A Margin	7.99K	14.93	69.49	934.87	48.8
EBITDA Margin %	-30.38K	25.54	-182	-3.16K	-76.17
EBITA Margin %	-30.49K	25.3	-183.2	-3.17K	-77.11
EBIT Margin %	-30.49K	25.3	-183.2	-3.17K	-77.11
Income From Continuing Operations Margin %	-30.55K	24.92	-185.5	-3.13K	-87.85
Net Income Margin %	-30.55K	24.92	-185.5	-3.13K	-87.85
Net Avail. For Common Margin %	-30.55K	24.92	-185.5	-3.13K	-87.85
Normalized Net Income Margin	-19.09K	15.58	-115.94	-1.96K	-54.91
Levered Free Cash Flow Margin	-18.41K	33.54	-169.4	-1.76K	-40.97
Unlevered Free Cash Flow Margin	-18.37K	33.65	-169.1	-1.76K	-34.05
Asset Turnover
Asset Turnover	0	0.49	0.15	0.02	0.6
Fixed Assets Turnover	0.06	32.81	7.47	0.77	11.49
Receivables Turnover (Average Receivables)	-	-	15.69	-	-
Short Term Liquidity
Current Ratio	13.56	6.07	8.31	3.36	0.8
Quick Ratio	13.47	5.95	8.19	3.28	0.77
Operating Cash Flow to Current Liabilities	-4.26	1.85	-4.41	-4.49	-0.66
Days Sales Outstanding (Average Receivables)	-	-	23.26	-	-
Average Days Payable Outstanding	33.8	35.69	32.37	29.21	27.48
Long Term Solvency
Total Debt/Equity	0.84	1.65	1.37	23.81	185.14
Total Debt / Total Capital	0.83	1.63	1.35	19.23	64.93
LT Debt/Equity	0.36	0.89	0.13	21.27	10.83
Long-Term Debt / Total Capital	0.36	0.88	0.13	17.18	3.8
Total Liabilities / Total Assets	6	15.44	10.11	34.64	76.04
EBIT / Interest Expense	-469.02	142.1	-377.11	-904.97	-6.96
EBITDA / Interest Expense	-458.77	150.79	-364.58	-883.29	-6.53
(EBITDA - Capex) / Interest Expense	-460.79	148.87	-374.26	-884.76	-6.55
Total Debt / EBITDA	-0.03	0.12	-0.04	-0.16	-0.88
Net Debt / EBITDA	3.06	-7.09	2.3	0.48	0.09
Total Debt / (EBITDA - Capex)	-0.03	0.12	-0.04	-0.16	-0.88
Net Debt / (EBITDA - Capex)	3.05	-7.18	2.24	0.48	0.09
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-19.35	69.16K	-70.58	-90.71	1.57K
Gross Profit, 1 Yr. Growth %	-7.71	-292.94	-151.39	89.49	-66.06
EBITDA, 1 Yr. Growth %	-3.99	-158.17	-309.66	61.03	-59.77
EBITA, 1 Yr. Growth %	-3.91	-157.42	-313.03	60.79	-59.48
EBIT, 1 Yr. Growth %	-3.91	-157.42	-313.03	60.79	-59.48
Earnings From Cont. Operations, 1 Yr. Growth %	-4.65	-156.5	-319.01	56.82	-53.26
Net Income, 1 Yr. Growth %	-4.65	-156.5	-319.01	56.82	-53.26
Normalized Net Income, 1 Yr. Growth %	-3.98	-156.5	-319.01	56.82	-53.26
Diluted EPS Before Extra, 1 Yr. Growth %	-18.82	-152.02	-318.8	56.71	-53.27
Accounts Receivable, 1 Yr. Growth %	-	-	-25.68	-	-
Net Property, Plant and Equip., 1 Yr. Growth %	-27.07	93.4	-4.06	-16.7	46.78
Total Assets, 1 Yr. Growth %	77.86	27.67	-31.52	-45.26	-23.1
Tangible Book Value, 1 Yr. Growth %	165.5	34.04	-31.68	-71.76	-120.65
Common Equity, 1 Yr. Growth %	91.32	14.83	-27.2	-60.2	-71.81
Cash From Operations, 1 Yr. Growth %	-2.18	-244.19	-210.86	15.59	-60.21
Capital Expenditures, 1 Yr. Growth %	187.59	79.7	306.21	-89.81	-32.08
Levered Free Cash Flow, 1 Yr. Growth %	6.86	-226.02	-248.61	-3.46	-61.23
Unlevered Free Cash Flow, 1 Yr. Growth %	6.98	-226.71	-247.85	-3.41	-67.74
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	23.72	2.26K	1.33K	-83.47	24.41
Gross Profit, 2 Yr. CAGR %	9.92	33.44	-0.43	-1.32	-19.8
EBITDA, 2 Yr. CAGR %	11.86	-25.22	10.44	83.74	-19.52
EBITA, 2 Yr. CAGR %	11.81	-25.68	10.6	85.08	-19.29
EBIT, 2 Yr. CAGR %	11.81	-25.68	10.6	85.08	-19.29
Earnings From Cont. Operations, 2 Yr. CAGR %	11.22	-26.6	11.24	85.32	-14.38
Net Income, 2 Yr. CAGR %	11.22	-26.6	11.24	85.32	-14.38
Normalized Net Income, 2 Yr. CAGR %	11.78	-26.35	11.24	85.32	-14.38
Diluted EPS Before Extra, 2 Yr. CAGR %	-0.4	-35.01	6.69	85.17	-14.41
Accounts Receivable, 2 Yr. CAGR %	-	-	-	-	-
Net Property, Plant and Equip., 2 Yr. CAGR %	89.91	18.77	36.22	-10.61	10.57
Total Assets, 2 Yr. CAGR %	28.27	50.69	-6.5	-38.77	-35.12
Tangible Book Value, 2 Yr. CAGR %	43.01	88.65	-4.3	-56.07	-75.85
Common Equity, 2 Yr. CAGR %	27.96	48.22	-8.57	-46.17	-66.5
Cash From Operations, 2 Yr. CAGR %	12.26	18.77	26.43	13.2	-32.18
Capital Expenditures, 2 Yr. CAGR %	-38.8	127.33	170.18	-35.67	-73.7
Levered Free Cash Flow, 2 Yr. CAGR %	11.62	16.11	36.85	19.78	-38.82
Unlevered Free Cash Flow, 2 Yr. CAGR %	11.66	16.5	36.88	19.51	-44.17
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	40.14	919.65	447.75	166.5	-23.06
Gross Profit, 3 Yr. CAGR %	17.65	32.59	-2.92	23.39	-30.86
EBITDA, 3 Yr. CAGR %	18.38	-10.01	5.44	25.23	10.74
EBITA, 3 Yr. CAGR %	18.27	-10.43	5.57	25.29	11.54
EBIT, 3 Yr. CAGR %	18.27	-10.43	5.57	25.29	11.54
Earnings From Cont. Operations, 3 Yr. CAGR %	17.69	-11.26	5.67	24.73	17.09
Net Income, 3 Yr. CAGR %	17.69	-11.26	5.67	24.73	17.09
Normalized Net Income, 3 Yr. CAGR %	16.96	-10.96	5.91	24.73	17.09
Diluted EPS Before Extra, 3 Yr. CAGR %	4.9	-19.79	-2.6	21.27	17.03
Net Property, Plant and Equip., 3 Yr. CAGR %	108.25	91.06	10.61	15.62	5.46
Total Assets, 3 Yr. CAGR %	31.44	28.07	15.86	-21.78	-33.94
Tangible Book Value, 3 Yr. CAGR %	54.65	39.96	34.47	-36.29	-65.85
Common Equity, 3 Yr. CAGR %	30.93	23.42	16.95	-30.7	-56.61
Cash From Operations, 3 Yr. CAGR %	15.61	22.03	16.07	22.71	-20.11
Capital Expenditures, 3 Yr. CAGR %	21.07	-12.37	175.86	-9.4	-34.5
Levered Free Cash Flow, 3 Yr. CAGR %	13.69	16.27	26.07	21.82	-17.76
Unlevered Free Cash Flow, 3 Yr. CAGR %	14.9	16.51	26.13	21.86	-22.76
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-36.39	131.46	254.63	96.06	202.76
Gross Profit, 5 Yr. CAGR %	29.66	31.45	10.05	17.81	-10.06
EBITDA, 5 Yr. CAGR %	27.25	3.02	15.16	19.73	-5.36
EBITA, 5 Yr. CAGR %	27.06	2.68	15.17	19.74	-5.18
EBIT, 5 Yr. CAGR %	27.06	2.68	15.17	19.74	-5.18
Earnings From Cont. Operations, 5 Yr. CAGR %	34.55	3.93	15.06	19.14	-2.86
Net Income, 5 Yr. CAGR %	50.46	3.93	15.06	19.14	-2.86
Normalized Net Income, 5 Yr. CAGR %	46.76	2.36	14.63	19.38	-2.73
Diluted EPS Before Extra, 5 Yr. CAGR %	9.7	-10.64	5.61	12.09	-7.51
Accounts Receivable, 5 Yr. CAGR %	-	-	180.89	-	-
Net Property, Plant and Equip., 5 Yr. CAGR %	41.99	66.68	75.73	41	10.59
Total Assets, 5 Yr. CAGR %	29.63	33.1	14.7	-4.67	-8.12
Tangible Book Value, 5 Yr. CAGR %	96.67	76.38	27.63	-11.96	-32.34
Common Equity, 5 Yr. CAGR %	30.47	30.91	13.41	-11.44	-29.07
Cash From Operations, 5 Yr. CAGR %	26.4	25.81	19.82	18.42	-6.38
Capital Expenditures, 5 Yr. CAGR %	-	26.45	66.91	-22.56	7.75
Levered Free Cash Flow, 5 Yr. CAGR %	26.13	21.83	22.47	17.66	-5.59
Unlevered Free Cash Flow, 5 Yr. CAGR %	26.2	21.92	23.26	17.7	-8.96